248 related articles for article (PubMed ID: 17710613)
1. Extrahepatic metabolism by CYP2E1 in PBPK modeling of lipophilic volatile organic chemicals: impacts on metabolic parameter estimation and prediction of dose metrics.
Yoon M; Madden MC; Barton HA
J Toxicol Environ Health A; 2007 Sep; 70(18):1527-41. PubMed ID: 17710613
[TBL] [Abstract][Full Text] [Related]
2. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of two different metabolic hypotheses for dichloromethane toxicity using physiologically based pharmacokinetic modeling for in vivo inhalation gas uptake data exposure in female B6C3F1 mice.
Evans MV; Caldwell JC
Toxicol Appl Pharmacol; 2010 May; 244(3):280-90. PubMed ID: 20153349
[TBL] [Abstract][Full Text] [Related]
4. Chloroethylene mixtures: pharmacokinetic modeling and in vitro metabolism of vinyl chloride, trichloroethylene, and trans-1,2-dichloroethylene in rat.
Barton HA; Creech JR; Godin CS; Randall GM; Seckel CS
Toxicol Appl Pharmacol; 1995 Feb; 130(2):237-47. PubMed ID: 7871537
[TBL] [Abstract][Full Text] [Related]
5. Tissue dosimetry expansion and cross-validation of rat and mouse physiologically based pharmacokinetic models for trichloroethylene.
Keys DA; Bruckner JV; Muralidhara S; Fisher JW
Toxicol Sci; 2003 Nov; 76(1):35-50. PubMed ID: 12915716
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
Clewell HJ; Gentry PR; Gearhart JM
J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
[TBL] [Abstract][Full Text] [Related]
7. Development of physiologically based toxicokinetic models for improving the human indoor exposure assessment to water contaminants: trichloroethylene and trihalomethanes.
Haddad S; Tardif GC; Tardif R
J Toxicol Environ Health A; 2006 Dec; 69(23):2095-136. PubMed ID: 17060096
[TBL] [Abstract][Full Text] [Related]
8. Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene.
Liao KH; Tan YM; Clewell HJ
Risk Anal; 2007 Oct; 27(5):1223-36. PubMed ID: 18076492
[TBL] [Abstract][Full Text] [Related]
9. Application of an updated physiologically based pharmacokinetic model for chloroform to evaluate CYP2E1-mediated renal toxicity in rats and mice.
Sasso AF; Schlosser PM; Kedderis GL; Genter MB; Snawder JE; Li Z; Rieth S; Lipscomb JC
Toxicol Sci; 2013 Feb; 131(2):360-74. PubMed ID: 23143927
[TBL] [Abstract][Full Text] [Related]
10. Chemical-specific screening criteria for interpretation of biomonitoring data for volatile organic compounds (VOCs)--application of steady-state PBPK model solutions.
Aylward LL; Kirman CR; Blount BC; Hays SM
Regul Toxicol Pharmacol; 2010 Oct; 58(1):33-44. PubMed ID: 20685286
[TBL] [Abstract][Full Text] [Related]
11. Uptake, distribution, and elimination of carbon tetrachloride in rat tissues following inhalation and ingestion exposures.
Sanzgiri UY; Srivatsan V; Muralidhara S; Dallas CE; Bruckner JV
Toxicol Appl Pharmacol; 1997 Mar; 143(1):120-9. PubMed ID: 9073600
[TBL] [Abstract][Full Text] [Related]
12. Development of an updated PBPK model for trichloroethylene and metabolites in mice, and its application to discern the role of oxidative metabolism in TCE-induced hepatomegaly.
Evans MV; Chiu WA; Okino MS; Caldwell JC
Toxicol Appl Pharmacol; 2009 May; 236(3):329-40. PubMed ID: 19249323
[TBL] [Abstract][Full Text] [Related]
13. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene.
Nong A; McCarver DG; Hines RN; Krishnan K
Toxicol Appl Pharmacol; 2006 Jul; 214(1):78-87. PubMed ID: 16464483
[TBL] [Abstract][Full Text] [Related]
14. Estimation of interindividual pharmacokinetic variability factor for inhaled volatile organic chemicals using a probability-bounds approach.
Nong A; Krishnan K
Regul Toxicol Pharmacol; 2007 Jun; 48(1):93-101. PubMed ID: 17367907
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and metabolism of vinyl fluoride in vivo and in vitro.
Cantoreggi S; Keller DA
Toxicol Appl Pharmacol; 1997 Mar; 143(1):130-9. PubMed ID: 9073601
[TBL] [Abstract][Full Text] [Related]
16. Predicting age-appropriate pharmacokinetics of six volatile organic compounds in the rat utilizing physiologically based pharmacokinetic modeling.
Rodriguez CE; Mahle DA; Gearhart JM; Mattie DR; Lipscomb JC; Cook RS; Barton HA
Toxicol Sci; 2007 Jul; 98(1):43-56. PubMed ID: 17426107
[TBL] [Abstract][Full Text] [Related]
17. Use of a physiologically based model to predict systemic uptake and respiratory elimination of perchloroethylene.
Dallas CE; Muralidhara S; Chen XM; Ramanathan R; Varkonyi P; Gallo JM; Bruckner JV
Toxicol Appl Pharmacol; 1994 Sep; 128(1):60-8. PubMed ID: 8079355
[TBL] [Abstract][Full Text] [Related]
18. Applications of sensitivity analysis to a physiologically based pharmacokinetic model for carbon tetrachloride in rats.
Evans MV; Crank WD; Yang HM; Simmons JE
Toxicol Appl Pharmacol; 1994 Sep; 128(1):36-44. PubMed ID: 8079352
[TBL] [Abstract][Full Text] [Related]
19. Steady-state solutions to PBPK models and their applications to risk assessment I: Route-to-route extrapolation of volatile chemicals.
Chiu WA; White P
Risk Anal; 2006 Jun; 26(3):769-80. PubMed ID: 16834633
[TBL] [Abstract][Full Text] [Related]
20. The utility of PBPK in the safety assessment of chloroform and carbon tetrachloride.
Delic JI; Lilly PD; MacDonald AJ; Loizou GD
Regul Toxicol Pharmacol; 2000 Oct; 32(2):144-55. PubMed ID: 11067771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
